Short answer: the drug leaves your body over a few weeks, and in the big withdrawal trials most people regained a large share of the weight they had lost within a year. One year after stopping semaglutide in the STEP 1 extension, people had regained about two-thirds of their prior weight loss, and most heart and metabolic improvements drifted back toward where they started (Wilding et al., 2022). Two randomized trials, STEP 4 for semaglutide and SURMOUNT-4 for tirzepatide, showed the same pattern when people were switched to placebo. Below is what the FDA labels and those trials actually report, with the numbers and where they come from.
How long the drug stays in your body
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are built to last a long time in the blood. That is why they are weekly shots. It is also why stopping is not like flipping a switch: the drug fades out over weeks.
Semaglutide. The Ozempic label says semaglutide has an elimination half-life of about 1 week and "will be present in the circulation for about 5 weeks after the last dose" (Ozempic label, DailyMed, section 12.3). The current Wegovy label gives the same 1-week half-life and says semaglutide stays in circulation for about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection or 25 mg tablet (Wegovy label, DailyMed, section 12.3).
Tirzepatide. The Zepbound label gives an elimination half-life of about 5 to 6 days in people with overweight or obesity (Zepbound label, DailyMed, section 12.3). Its overdose section rounds this to about 5 days. Unlike the semaglutide labels, the Zepbound label does not state a number of weeks until the drug is gone, so we will not invent one here.
In plain terms: some of the drug is still in your blood for several weeks after the last dose, so the change is gradual rather than overnight.
STEP 1 extension: what happened a year after stopping semaglutide
STEP 1 gave adults with obesity or overweight (and no diabetes) weekly semaglutide 2.4 mg or placebo for 68 weeks, alongside a lifestyle program. At week 68, both the drug and the lifestyle program stopped. A subset of 327 people was then followed off treatment for another year (Wilding et al., Diabetes Obes Metab 2022).
- On treatment (week 0 to 68): average weight loss was 17.3% with semaglutide and 2.0% with placebo.
- After stopping (week 68 to 120): the semaglutide group regained 11.6 percentage points of that loss. The placebo group regained 1.9 points.
- Net at week 120: the semaglutide group was still 5.6% below its starting weight on average; the placebo group was 0.1% below.
- Health markers: the authors report that cardiometabolic improvements seen during treatment "reverted towards baseline" for most variables by week 120.
Two things to keep in mind. These analyses were labelled exploratory by the authors. And the lifestyle program stopped at the same time as the drug, so the study cannot separate the two.
STEP 4: keep going vs switch to placebo (semaglutide)
STEP 4 asked the question more directly with a randomized, double-blind design (Rubino et al., JAMA 2021). Everyone took semaglutide for a 20-week run-in, stepping up to 2.4 mg weekly. That run-in produced an average weight loss of 10.6%. Then 803 people were randomly split: two-thirds continued semaglutide and one-third were switched to placebo for 48 more weeks. Both groups kept a lifestyle program.
- Continued semaglutide: body weight changed by -7.9% from week 20 to week 68 (they kept losing).
- Switched to placebo: body weight changed by +6.9% over the same period (they regained).
- Waist size, systolic blood pressure and a physical function score were all better in the group that continued.
- Stomach and gut side effects were reported in 49.1% of the continued group vs 26.1% of the placebo group.
SURMOUNT-4: keep going vs switch to placebo (tirzepatide)
SURMOUNT-4 ran the same kind of test for tirzepatide (Aronne et al., JAMA 2024). A total of 783 adults with obesity or overweight (no diabetes) took open-label tirzepatide at their maximum tolerated dose, 10 or 15 mg weekly, for 36 weeks. The 670 who completed that phase had lost 20.9% of their weight on average. They were then randomized 1:1 to keep taking tirzepatide or switch to placebo for 52 weeks, with diet and activity advice in both groups.
- Continued tirzepatide: weight changed by -5.5% from week 36 to week 88.
- Switched to placebo: weight changed by +14.0% over the same period.
- Kept at least 80% of the lead-in loss: 89.5% of the continued group vs 16.6% of the placebo group.
- Overall from week 0 to 88: average loss of 25.3% with continued tirzepatide vs 9.9% in the group switched to placebo.
The authors conclude that withdrawing tirzepatide "led to substantial regain of lost weight."
What these trials do and do not tell you
- They report averages. Some people regained more, some less. The abstracts do not tell any single person what will happen to them.
- All three studied adults with obesity or overweight without diabetes. People taking Ozempic or Mounjaro for type 2 diabetes were not studied in these trials.
- Stopping in the trials was abrupt. They did not test tapering down slowly, so they cannot say whether that changes the result.
- Several authors of each paper worked for the drug maker (Novo Nordisk for STEP, Eli Lilly for SURMOUNT), as listed in the papers' disclosures.
Talk to your prescriber before changing anything
Whether to stop, pause, lower or keep a dose is a decision for you and the person who prescribes it. Costs, side effects, supply, pregnancy plans and other health issues all change the answer, and this article cannot weigh those for you. If you are thinking about stopping, bring these trial results to that conversation and ask what a plan would look like for you, including what to watch for afterward.
Why tracking helps
Whatever you and your clinician decide, a written record makes it easier to see what is really happening. Logging each dose, the date you stopped or changed it, your weight and any side effects gives you both real data instead of memory. A GLP-1 tracker such as Dose Track keeps those logs in one place. If you are on Wegovy, the Wegovy page has the dose steps, and the Zepbound page covers tirzepatide.
Sources
- Ozempic (semaglutide) injection label, DailyMed setid adec4fd2-6858-4c99-91d4-531f5f2a2d79, section 12.3.
- Wegovy (semaglutide) label, DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, section 12.3.
- Zepbound (tirzepatide) label, DailyMed setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, sections 10 and 12.3.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID 35441470.
- Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. PMID 33755728.
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. PMID 38078870.
This article summarizes published labels and research for general information. It is not medical advice.

